Abstract:Objective:(CA)n repeat polymorphism in intron 1 and EGFR mutations were analyzed for its association with molecular targeted therapy responsiveness in lung cancer.Methods:Both of observed group consisted of 116 somatic specimens of lung cancer and control group consisted of 20 peripheral blood samples were analyzed by direct DNA sequencing.Epidermal growth factor receptor mutations at exons 18、19、21 were analyzed for overall 136 specimens.CA repeat polymorphisms in intron 1 of EGFR from 48 specimens were also analyzed by direct sequencing.45 lung cancer patients were followed up for their treatment outcome of molecular targeted drug(EGFR Tyrosine kinase inhibitors)molecular targeted drug.In addition,we analyzed(CA)n dinucleotide repeat polymorphism in intron 1 of EGFR followed EGFR mutations data in exons 18、19、21 for their association with clinical outcome in lung cancer patients treated with molecular targeted drug.Results:EGFR mutations were identified in 20 patients(17.25%)out of 116 somatic specimens including 17 mutations in extron domain and 3 heterozygosis in intron domain.None mutation was found in 20 peripheral blood samples in control group.Although the mutant frequency in the adenocarcinoma(21.62%)was a little higher than in the squamous cell carcinoma(8.33%)and in other histological types(11.11%)of lung cancer,there was no significant difference between them.The rate of mutations in female patients(7/36,19.45%)was a little higher than those in male patients(13/80,16.25%),but there was also no significant difference between them.Response rate to EGFR TKIs was significantly higher in the patients with EGFR mutations(62.5%)than those without mutation(0%)in observed groups(P0.01).Disease control rate to EGFR TKIs was significantly higher in the patients with EGFR mutations(100%)than those without mutation(44.4%)in observed group(P0.05).In patients harboring EGFR mutations,disease control rate to patients treated with EGFR TKls(100%)was significantly higher than those who never treated with it(40%)(P0.05).Two of three patients with heterozygosis in intron domain treated with EGFR TKls,the response rate was 0% and the disease control rate was 1/2.The frequency distribution of EGFR intron 1(CA)n repeat in 48 cases was 23(47.9%)low(CA)n repeat(CA≤16)and 25(52.1%)high ones(CA16)in cases and controls.There was no statistical correlation between the length of(CA)n repeat in intron 1 and gene mutations of EGFR(P0.05,OR﹤2).There was no significant difference in response rate and disease control rate of EGFR TKIs treatment between low and high(CA)n repeat numbers both in 16 patients with mutations and 18 patients without mutations in observed group(P0.05).Conclusion:Response rate(62.5% vs 0)and disease control rate(100% vs 44.4%)to EGFR TKIs treatment were significantly higher in the patients with EGFR mutations than who without it.Our results once again showed that somatic mutations of EGFR was a major determinant of EGFR TKIs response in lung cancer.There was no statistical correlation between the length of(CA)n repeat in intron 1 and mutations of EGFR.There was no significant difference in response rate and disease control rate of EGFR TKIs treatment between low(CA)n repeat patients and high repeat ones,cohsidering of the mutant factor.As the presents of certain disease control rate in the non-mutation lung cancer patients treated with EGFR TKls,the relationship between the length of(CA)n repeat and molecular targeted drug sensitivity need to be studied furthermore.

Exploring the relationship between polymorphic (TG/CA) n repeats in intron 1 regions and gene expression

Association of the EGFR intron 1 CA repeat length with lung cancer risk.

Genome-wide Analysis of Long Non-Coding RNA Expression and Function in Colorectal Cancer

A Novel Analytical Strategy To Identify Fusion Transcripts Between Repetitive Elements And Protein Coding-Exons Using Rna-Seq

Nucleotide Excision Repair Gene ERCC1 19007T>C Polymorphism Contributes to Lung Cancer Susceptibility: A Meta-Analysis

Correlations of Single Nucleotide Polymorphisms of DNA Repair Gene XRCC1 to Risk of Colorectal Cancer

Identification of a Novel VNTR Polymorphism in C6orf37 and Its Association with Colorectal Cancer Risk in Chinese Population

Repeat polymorphisms underlie top genetic risk loci for glaucoma and colorectal cancer

Shorter EGFR Dinucleotide Repeat Length Predicts Better Response of Patients with Advanced Non-small Cell Lung Cancer to EGFR Tyrosine Kinase Inhibitor

Polymorphic tandem repeats shape single-cell gene expression across the immune landscape

Intron 1 (ca)n Dinucleotide Repeat Polymorphism and Mutations of Epidermal Growth Factor Receptor and Responsiveness of Molecular Targeted Therapy in Lung Cancer

Functional Variable Number of Tandem Repeats Variation in the Promoter of Proto-Oncogene Pttg1ip is Associated with Risk of Estrogen Receptor-Positive Breast Cancer

Polymorphic Loci and Polymorphism Analysis of Short Tandem Repeats Within XNP Gene

Polymorphism in Epidermal Growth Factor Receptor Intron 1 Predicts Prognosis of Patients with Esophageal Cancer after Chemoradiation and Surgery

Genomic Repeats Categorize Genes with Distinct Functions for Orchestrated Regulation.

Genome-wide Investigation of VNTR Motif Polymorphisms in 8,222 Genomes: Implications for Biological Regulation and Human Traits

A Novel Variable Number of Tandem Repeats (VNTR) Polymorphism Containing Sp1 Binding Elements in the Promoter of XRCC5 is a Risk Factor for Human Bladder Cancer.

The Relationship Of Egfr Intron 1 (Ca) And Microsatellite Polymorphism And The Efficacy Of Egfr-Tki In Advanced Nsclc Patients

Tri-nucleotide Repeats and Their Association with Genes in Rice Genome.

Insights into the causes and consequences of DNA repeat expansions from 700,000 biobank participants

Polymorphic tandem DNA repeats activate the human telomerase reverse transcriptase gene